Expression and prognostic value of prl-3 in human intrahepatic cholangiocarcinoma

Pathology and Oncology Research

Volumn 16, Issue 2, 2010, Pages 169-175

  Xu, Yijun ^a   Zhu, Mingchen ^b   Zhang, Shuhong ^a   Liu, Hui ^a   Li, Tao ^a   Qin, Chengyong ^a  

^a SHANDONG UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

Immunochemistry; Intrahepatic cholangiocarcinoma; Lymph node metastasis; PRL 3; Prognosis

Indexed keywords

PHOSPHATASE OF REGENERATING LIVER 3; PROTEIN PRL 3; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC CHOLANGIOCARCINOMA; LIVER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN TYROSINE PHOSPHATASES; TUMOR MARKERS, BIOLOGICAL;

EID: 77955678049     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-009-9200-y     Document Type: Article

References (37)

1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366:1303-1314
2. Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353-1357
3. Shaib Y, EI-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115-125
4. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA et al (2001) Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48:816-820
5. Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E (2002) Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res 22:3637-3641
6. Okuda K, Nakanuma Y, Miyazaki M (2002) Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 17:1049-1055 (Pubitemid 35013958)
7. Okuda K, Nakanuma Y, Miyazaki M (2002) Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol 17:1056-1063 (Pubitemid 35013959)
8. Anderson CD, Pinson CW, Berlin J, Chari RS (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9:43-57
9. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, Kudo T et al (2005) Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 29:728-733
10. Yamamoto M, Takasaki K, Yoshikawa T (1999) Lymph node metastasis in intrahepatic cholangiocarcinoma. Jpn J Clin Oncol 29:147-150
11. Harada K, Masuda S, Hirano M, Nakanuma Y (2003) Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 34:857-863
12. Shimonishi T, Miyazaki K, Kono N, Sabit H, Tuneyama K, Harada K, Hirabayashi J et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302-310
13. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A et al (2004) Protein tyrosine phosphatases in the human genome. Cell 117:699-711 (Pubitemid 38748887)
14. Stoker AW (2005) Protein tyrosine phosphatases and signalling. J Endocrinol 185:19-33
15. van Huijsduijnen RH, Bombrun A, Swinnen D (2002) Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 7:1013-1019
16. Zeng Q, Hong W, Tan YH (1998) Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 244:421-427
17. Mohn KL, Laz TM, Hsu JC, Melby AE, Bravo R, Taub R (1991) The immediate-early growth response in regenerating liver and insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and identification of 41 novel immediate-early genes. Mol Cell Biol 11:381-390
18. Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R (1994) PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cel Biol 14:3752-3762
19. Werner SR, Lee PA, DeCamp MW, Crowell DN, Randall SK, Crowell PL (2003) Enhanced cell cycle progression and down regulation of p21Cip1/Waf1 by PRL tyrosine phosphatases. Cancer Lett 202:201-211
20. Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, Johnson B et al (2001) Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun 283:1061-1068
21. Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, Pallen CJ et al (2003) PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63:2716-2722
22. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE et al (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294:1343-1346
23. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, Zhang M et al (2004) Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 164:2039-2054
24. Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H (2004) High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 10:7318-7328
25. Qian F, Li YP, Sheng X, Zhang ZC, Song R, Dong W, Cao SX et al (2007) PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Mol Med 13:151-159
26. Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, Lengauer C (2003) PRL-3 expression in metastatic cancers. Clin Cancer Res 9:5607-5615
27. Miskad UA, Semba S, Kato H, Yokozaki H (2004) Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology 71:176-184
28. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N et al (2007) High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch 450:303-310
29. Wang L, Peng L, Dong B, Kong L, Yan L, Xie Y, Shou C (2006) Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol 17:1517-1522
30. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, Bardelli A et al (2005) PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 11:6835-6839
31. Ren T, Jiang B, Xing X, Dong B, Peng L, Meng L, Xu H et al (2009) Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer. Pathol Oncol Res (Epub ahead of print)
32. Nakanuma Y, Sripa B, Vatanasapt V, Leong ASY, Ponchon T, Ishak KG (2000) Intrahepatic cholangiocarcinoma. In: Hamilton SR, Aaltonen LA (eds) World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. IARC Press, Lyon, pp 173-180
33. Junking M, Wongkham C, Sripa B, Sawanyawisuth K, Araki N, Wongkham S (2008) Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma. Eur J Cancer 44:619-626
34. Peng L, Ning J, Meng L, Shou C (2004) The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 130:521-526
35. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr (1993) Diagnostic role of serum CA19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 68:874-879
36. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95:204-207
37. Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI (2008) What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 23:766-770